BBIO — Q2 2026 Financial Report Analysis

BridgeBio's second quarter of 2026 was about one drug and one financing. U.S. sales of Attruby, its heart drug, reached $222.4 million, up from $71.5 million a year earlier and from $180.6 million in the first quarter. That pushed total revenue to $243.7 million (+120.4%). The company still lost money ($152.2 million, or $0.78 a share), because it is spending heavily to run the Attruby launch and to prepare three more drugs that are now under FDA review. Then, the day after the quarter ended, it raised $933.9 million in preferred stock. Its cash at June 30 was $720.2 million, and that raise is what it now relies on to fund those launches.

At a glance

• Attruby sales up 23% in three months ($180.6M in Q1 to $222.4M in Q2). The launch is still growing quickly about a year and a half after the November 2024 approval, and management says most of the growth comes from patients who had never been treated before.
• Operating loss of $107.1 million, down from $134.3 million a year ago. Revenue is growing faster than costs. But costs still grew 43% ($350.8M vs $244.8M), so the company is not yet close to breaking even.
• $720.2 million in cash at June 30, plus $933.9 million raised on July 1. Operations used $268.4 million of cash in the first half of 2026. The new money comes as preferred stock that pays a 7% annual dividend, so it carries an ongoing cost.

What BridgeBio sells, in plain terms

ATTR-CM (transthyretin amyloid cardiomyopathy) is a disease in which a blood protein called transthyretin (TTR) falls apart. Its pieces build up as stiff deposits in the heart muscle, and this slowly causes heart failure. Attruby (acoramidis) is a pill that holds the TTR protein together so it doesn't break down. The company calls it a "near-complete (≥90%)" stabilizer. The established drug in this market is tafamidis, and BridgeBio's sales pitch is that Attruby works better and faster. Outside the U.S. the same drug is sold by partners as Beyonttra, and BridgeBio receives a royalty (a percentage of their sales) on it.

The numbers

The year-ago quarter was Attruby's second full quarter on the market, so the +211% growth rate mostly shows how small the starting point was. The quarter-on-quarter change is a better measure of where the launch stands now. Attruby added $41.8 million of sales between Q1 and Q2 2026 (+23.2%).

Operating margin is the share of revenue left after running the business, before interest and tax. Here it is negative because the company spends more than it brings in. The direction is what matters: it improved from -121.4% to -43.9% in a year.

What drove revenue

The 10-Q attributes the Attruby increase "primarily [to] continued commercial expansion driven by patient demand". The earnings release adds that growth was "led by the treatment-naïve segment", meaning patients starting their first ATTR-CM drug rather than switching from tafamidis. The chief commercial officer said Attruby's "first-line share" (its share of new patients) rose again. The company does not disclose patient counts or the size of that share, so we can't check either claim against a number.

Royalty revenue rose by $13.8 million, mainly from partner sales of Beyonttra in the EU and Japan. It is small for now, but it is the fastest-growing revenue line in percentage terms.

Where the money went

Selling, general and administrative costs rose $57.1 million (+44.2%). According to the 10-Q, $29.9 million of that came from external costs, $22.0 million from more staff and $5.2 million from stock-based pay. The money is going to the ongoing Attruby launch and to pre-launch work for three drugs that are not yet approved. The release says the U.S. sales and medical teams for the muscle-disease drug (BBP-418) are already hired and trained, before any FDA decision.

R&D rose $38.2 million (+34.4%), mostly on the three late-stage drugs:

Spending on acoramidis is still rising after approval. That reflects new studies, including ASCEND-ATTR, a Phase 4 imaging study that will follow patients' hearts for 36 months.

What the headline numbers hide

• The year-ago revenue included a one-off. Q2 2025 included $30.0 million of regulatory-milestone revenue, a one-time payment from a partner when a drug reached an approval step, and this year's quarter had nothing similar. That makes total-revenue growth (+120%) look smaller than the underlying trend. Product sales alone grew 211%. For the half year the effect is bigger: H1 2025 included $105.0 million of milestone revenue.
• About $40 million a quarter of the loss is non-cash interest on royalty deals. BridgeBio has previously sold part of its future royalties to investors in exchange for upfront cash. Accounting treats that cash as a loan and charges interest on it, which was $41.3 million in Q2 (vs $26.0M a year ago). Separately, the convertible notes cost $13.3 million in interest. Those two items together are larger than the $27.2 million improvement in operating loss. The company is now carrying $879.4 million of deferred royalty obligations and about $2.48 billion of convertible notes (net carrying value: notes due 2027, 2029, 2031 and 2033). Shareholders' equity is negative at -$2.52 billion, meaning liabilities exceed assets on the balance sheet.
• Cash burn is falling only slowly. Operating cash outflow for the first six months was $268.4 million vs $279.9 million a year earlier. The net loss narrowed by more than that because about $134 million went into working capital, mostly receivables, which rose $115.0 million (+82.5%) since December to $254.5 million. That is slightly more than a full quarter's revenue. Five customers (specialty pharmacies and distributors) made up about 94% of gross revenue in the quarter, the largest at 28.8%. So this looks like money owed by a few large buyers during a fast-growing launch rather than bad debt, but it is worth checking that receivables stop growing faster than sales.
• Discounts are growing with sales. BridgeBio doesn't disclose its gross-to-net discount, the gap between list price and what it actually receives after rebates, chargebacks and co-pay help. The reserve for accrued rebates rose to $80.0 million from $45.9 million (+74%) in six months. Because this filing doesn't give Q4 2025 product sales, we can't tell whether that rise simply follows sales volume or means discounts got deeper per prescription.
• Share buybacks haven't reduced the share count. BridgeBio spent $210.0 million buying back stock in H1 2026: $82.5 million from buyers of its new 2033 notes and $127.5 million on the open market at an average $66.96 under a new $500 million program. Even so, the average share count was 2.8% higher than a year ago (195.8M vs 190.5M), because stock options were exercised and employee shares were issued. None of the per-share improvement came from a smaller share count.
• The new money has a cost. The $933.9 million of Series A preferred stock pays a dividend of 7% a year. At the initial rate that is about $65 million a year (our calculation). It can be paid in cash or added to the amount owed to holders. The rate rises by 5 percentage points after seven years and keeps stepping up to a 17% cap after that. Holders can convert into common stock at $137.79 a share. The money arrived after June 30, so none of this is in Q2's numbers. It will start reducing what common shareholders earn from Q3.

Takeaway: Attruby is growing quickly. It added $41.8 million of quarterly sales in three months at a 95% product gross margin, and the operating loss has been cut by a fifth in a year. But BridgeBio is paying for that growth, plus three more launches, with borrowed and preferred money, not with its own cash flow. It now owes about $3.4 billion in convertible notes and royalty obligations, plus the new preferred stock. Whether Attruby sales can keep growing about 20% a quarter until those launches start to pay off matters more for this company than any single quarter's loss.

What's next

Management gave no revenue or profit guidance. The milestones it did set out:

• BBP-418 for LGMD2I/R9 (an inherited muscle-wasting disease with no approved treatment): FDA decision due November 27, 2026, with Priority Review and no advisory committee planned.
• Encaleret for ADH1 (a genetic disorder that causes low blood calcium): FDA decision due May 8, 2027, also with Priority Review. An EU application has been filed, and a Phase 3 trial in chronic hypoparathyroidism, a much larger patient group (about 200,000 patients in the U.S. and EU), is screening patients, with results expected in late 2027 or early 2028.
• Oral infigratinib for achondroplasia (the most common form of dwarfism): the application has been submitted to the FDA and the company expects a mid-2027 U.S. launch. A Phase 2 update in hypochondroplasia is due in the second half of 2026.
• A Commercial Day on October 8, 2026 to explain how the three launches will be run.
• On August 31, 2026, BridgeBio announced a drug-pricing agreement with the U.S. government. The company expects its pricing commitment for future medicines to exclude drugs approved only for orphan (rare-disease) indications.

The cash, together with what management calls "increasing cash collections" from Attruby and Beyonttra, is expected to fund operations for at least 12 months from the filing date. Twelve months is the minimum period companies must assess under accounting rules, so this statement is not a long-range funding forecast. Our view is that the next two quarters should show whether Attruby keeps adding about $40 million of quarterly sales while SG&A ramps up again for the BBP-418 launch. If Attruby keeps growing at that pace, operating losses should keep shrinking even with a fourth launch. If sales growth slows, the 7% preferred dividend and the 2027 note maturity would leave the company with less financial room.

Source: BridgeBio Pharma Form 10-Q for the quarter ended June 30, 2026 (filed August 10, 2026), with figures cross-checked against the same-day earnings release (Form 8-K, Exhibit 99.1).